Stock · FRE.DE · Healthcare
Germany · Large Cap · Revenue 12 mo. €23.4B
Price as of 11/06/2026
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa.
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition products; and medical technologies that include disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment operates hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, as well as provision of medical diagnostics. The company has a strategic collaboration with SAP SE and Avelios Medical GmbH for the development of a cloud-native, modular hospital information system that enables digitalization of clinical and administrative processes with AI integration. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.
Original text from the data provider
Summary
49.3 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €1.2B (2025), it supports €13.3B. The remaining €13.5B of the market value assume it grows 9.8% a year for 10 years and not at all afterwards.
Required FCF growth per year
9.8%
no growth afterwards
Price to operating cash flow 10.0×, above its usual range.
Middle half of 20 quarters: 3.5× to 7.9×, median 4.1×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
No indication in the stored figures.
with respect to the priced-in expectation
Since the last quarter
Q1 → Q2 2026
8 more unchanged: Revenue, 12 mo., FCF, 12 mo., Gross margin, EBIT margin, FCF margin, Net debt, Shares outstanding, Return on equity
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 6.62% | 11.52% | Rank 23 |
| Return on capital (Greenblatt) | 17.62% | 32.55% | Rank 20 |
| EBIT margin | 9.52% | 18.31% | Rank 25 |
| FCF margin | 5.24% | 14.12% | Rank 22 |
| Gross margin | 24.89% | 60.99% | Rank 13 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 4.76% | 8.04% | Rank 33 |
| Earnings growth, 3 years per year | −2.81% | 5.44% | Rank 30 |
| Earnings growth, 5 years per year | −6.02% | 7.00% | Rank 16 |
| Sustainable growth (ROE × retained earnings) | 6.54% | 3.66% | Rank 81 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 4.28% | 2.90% | Rank 72 |
| FCF yield | 4.47% | 3.63% | Rank 62 |
| EV/saleslower is better | 1.62 | 4.03 | Rank 82 |
| EV/EBITlower is better | 17.05 | 21.73 | Rank 72 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | −0.84% | 8.66% | Rank 40 |
| Share price, 6 months | 28.61% | 24.27% | Rank 62 |
| Share price, 3 months | 16.65% | 15.42% | Rank 52 |
| Distance from 52-week high | 0.00% | −7.35% | Rank 96 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | −1.15% | 0.30% | Rank 62 |
| Change in share countlower is better | 0.00% | 0.00% | Rank 45 |
| Dividend streak in years | 1 | 10 | Rank 29 |
| Price reaction to results, market-adjusted | 3.51% | 0.05% | Rank 77 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 46.15% | 48.40% | Rank 44 |
| Net debt/EBITDAlower is better | 2.76 | 1.11 | Rank 18 |
| Debt to equitylower is better | 0.62 | 0.48 | Rank 43 |
| Volatility, 1 yearlower is better | 25.39% | 31.42% | Rank 86 |
Ten years in figures
| Year | Revenue, €B | EBIT margin | FCF | Shares | Net debt, €B |
|---|---|---|---|---|---|
| 2016 | 29.1 | 14.9% | €1.9B | 551M | 13.3 |
| 2017 | 33.9 | 13.5% | −€4.2B | 559M | 17.4 |
| 2018 | 33.5 | 13.3% | €523.0M | 558M | 16.4 |
| 2019 | 35.4 | 13.1% | €1.8B | 557M | 25.6 |
| 2020 | 36.3 | 12.1% | €4.1B | 558M | 24.1 |
| 2021 | 37.1 | 9.7% | €3.0B | 558M | 24.5 |
| 2022 | 21.3 | 7.0% | €2.3B | 561M | 25.6 |
| 2023 | 21.1 | 6.4% | €3.3B | 563M | 13.3 |
| 2024 | 21.8 | 8.4% | €1.5B | 563M | 11.5 |
| 2025 | 22.9 | 9.5% | €1.2B | 563M | 10.3 |
1 of 7 StockScorer Score rules met · How the score is built
Fresenius SE & Co. KGaA mainly meets criteria in the Valuation category. Result from 18 strategies checked.
Fresenius SE & Co. KGaA is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
1 of 7 rules met
2 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Fresenius SE & Co. KGaA.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 23.4 | 30.0 |
| P/B ratio | 1.5 | 4.8 |
| Return on equity (ROE) | 6.6% | 11.5% |
| Equity ratio | 46.2% | 48.4% |
| Debt-to-equity (D/E) | 0.62 | 0.48 |
| Dividend yield | 2.0% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| FRE.DE | Fresenius SE & Co. KGaAthis page | |
| FMS | Fresenius Medical Care Corporation | locked |
| THC | Tenet Healthcare Corporation | locked |
| 4013.SR | Dr Sulaiman Al Habib Medical Group | locked |
| 5225.KL | IHH Healthcare Bhd | locked |
| EHC | Encompass Health Corp | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.